Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
Table 1
Distribution of included patients in vonoprazan-based therapy of H. pylori in recent years.
Title
Year
Authors
Number of patients
“Vonoprazan, A Novel Potassium-Competitive Acid Blocker, as a Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-Blind Study”
2016
Murakami et al.
650
“Randomised Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Doses of TAK-438 (Vonoprazan), a Novel Potassium-Competitive Acid Blocker, in Healthy Male Subjects”
2015
Jenkins et al.
60
“Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/Non-Japanese Subjects”
2015
Sakurai et al.
84
“Vonoprazan versus Conventional Proton Pump Inhibitor-Based Triple Therapy as First-Line Treatment against Helicobacter pylori: A Multicenter Retrospective Study in Clinical Practice”
2016
Shichijo et al.
2715
“Safety and Sfficacy of Vonoprazan-Based Triple Therapy against Helicobacter pylori Infection: A Single-Center Experience with 1118 Patients”
2016
Nakao et al.
1172
“Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance”
2016
Matsumoto et al.
125
“A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-Containing 7-Day Triple Therapy against Helicobacter pylori”
2016
Noda et al.
146
“Usefulness of Vonoprazan, a Potassium Ion-Competitive Acid Blocker, for Primary Eradication of Helicobacter pylori”
2016
Yamada et al.
2507
“Vonoprazan Improves the Afficacy of Helicobacter pylori Eradication Therapy with a Regimen Consisting of Clarithromycin and Metronidazole in Patients Allergic to Penicillin”
